Stifel Nicolaus Keeps Their Buy Rating on Spyre Therapeutics (SYRE)
In a report released yesterday, Alex Thompson CFA from Stifel Nicolaus reiterated a Buy rating on Spyre Therapeutics (SYRE – Research Report).
Stifel Nicolaus Remains a Buy on X4 Pharmaceuticals (XFOR)
In a report released yesterday, Stephen Willey from Stifel Nicolaus maintained a Buy rating on X4 Pharmaceuticals (XFOR – Research Report). The ...
Accolade’s (ACCD) “Hold” Rating Reiterated at Stifel Nicolaus
Stifel Nicolaus reaffirmed their hold rating on shares of Accolade (NASDAQ:ACCD – Free Report) in a research note published ...
Stifel Nicolaus Issues Pessimistic Forecast for Jack in the Box (NASDAQ:JACK) Stock Price
Jack in the Box (NASDAQ:JACK – Get Free Report) had its price objective reduced by research analysts at Stifel Nicolaus from ...
Stifel Nicolaus Raises Astera Labs (ALAB) Price Target, Cites AI Infrastructure Benefits
We recently published a list of Top 10 AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at ...
Stifel Announces Acquisition of Bryan, Garnier & Co.
Expands European Advisory Footprint in Healthcare & Technology VerticalsST. LOUIS and PARIS, Jan. 06, 2025 (GLOBE NEWSWIRE) -- . (NYSE: SF) today announced it has signed a definitive agreement to ...